Pediatric blood & cancer · 2025
Targeted Therapy in Pediatric Langerhans Cell Histiocytosis: Describing a Novel Strategy to Minimize Long-Term Exposure While Maintaining Efficacy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wojciechowska Natalia, Richards Alexandra E, Anthony Aly, Diaz Maranda, Vallance Kelly, Greer Chelsee, Ray Anish
Аннотация
BACKGROUND: Langerhans cell histiocytosis (LCH) is a rare malignancy driven by MAPK pathway activation and often involves BRAF V600E mutations. Targeted therapy with trametinib, a MEK inhibitor, is a promising alternative to conventional chemotherapy.
PROCEDURE: We retrospectively analyzed the records of patients treated with trametinib either at relapse or as front-line therapy between 2020 and 2024.
RESULTS: Fifteen pediatric patients received trametinib either at diagnosis (n = 6), relapse (n = 7), or due to chemotherapy intolerance (n = 2). Molecular testing identified MAPK pathway mutations in 11 patients. The median age at treatment initiation was 5 years (range: 0.1-16.5). Notably, five of these patients started trametinib before the age of 1. The median treatment duration was 2.2 years (range: 0.1-4.7 years). All 15 patients achieved favorable responses without concerns regarding growth and development. The adverse effects included rash (40%) and diarrhea (13%), which were all mild and were managed with temporary dose adjustments. A self-weaning dosing strategy minimized long-term exposure while maintaining disease control.
CONCLUSION: Our data suggest that trametinib is a safe and effective therapy for pediatric LCH with broad efficacy and tolerability. However, prospective studies are needed to confirm these findings and refine targeted treatment protocols.
PROCEDURE: We retrospectively analyzed the records of patients treated with trametinib either at relapse or as front-line therapy between 2020 and 2024.
RESULTS: Fifteen pediatric patients received trametinib either at diagnosis (n = 6), relapse (n = 7), or due to chemotherapy intolerance (n = 2). Molecular testing identified MAPK pathway mutations in 11 patients. The median age at treatment initiation was 5 years (range: 0.1-16.5). Notably, five of these patients started trametinib before the age of 1. The median treatment duration was 2.2 years (range: 0.1-4.7 years). All 15 patients achieved favorable responses without concerns regarding growth and development. The adverse effects included rash (40%) and diarrhea (13%), which were all mild and were managed with temporary dose adjustments. A self-weaning dosing strategy minimized long-term exposure while maintaining disease control.
CONCLUSION: Our data suggest that trametinib is a safe and effective therapy for pediatric LCH with broad efficacy and tolerability. However, prospective studies are needed to confirm these findings and refine targeted treatment protocols.